ASCO 2025 | Evaluating lifileucel as a second-line therapy for melanoma
Theresa Medina, MD, University of Colorado Comprehensive Cancer Center, Aurora, CO, comments on the emerging promise of lifileucel as a second-line treatment for patients with melanoma who are resistant or non-responsive to first-line checkpoint inhibitors. Participants in the C-144-01 trial (NCT02360579) demonstrated a durable and deepening response after only a single infusion of lifileucel, suggesting that extended treatment may not be essential for sustained benefit. This interview took place at the 2025 American Society of Clinical Oncology (ASCO) meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
This is an exciting opportunity for patients who are resistant to checkpoint inhibitor therapy or who may never respond to immune checkpoint inhibitor therapy. The patients again demonstrate a durable response. We also can see that the responses deepen over time. So patients who initially have a partial response, we can see that they convert to a complete response after just a single infusion of therapy...
This is an exciting opportunity for patients who are resistant to checkpoint inhibitor therapy or who may never respond to immune checkpoint inhibitor therapy. The patients again demonstrate a durable response. We also can see that the responses deepen over time. So patients who initially have a partial response, we can see that they convert to a complete response after just a single infusion of therapy. So they don’t really need to receive ongoing therapy. So for patients, again, that are resistant, I think this is a great option that all patients should be presented with if they don’t respond or progress after an initial line of therapy.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
